Teva Pharmaceutical Industries (NYSE:TEVA) Insider Sells $285,236.70 in Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) insider Brian Savage sold 7,342 shares of the business’s stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $38.85, for a total transaction of $285,236.70. Following the completion of the transaction, the insider directly owned 8,500 shares of the company’s stock, valued at approximately $330,225. This represents a 46.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Teva Pharmaceutical Industries Trading Up 3.0%

NYSE TEVA opened at $40.18 on Friday. The stock’s 50-day simple moving average is $36.04 and its two-hundred day simple moving average is $33.76. Teva Pharmaceutical Industries Ltd. has a twelve month low of $18.21 and a twelve month high of $40.79. The company has a quick ratio of 0.67, a current ratio of 0.88 and a debt-to-equity ratio of 1.56. The company has a market capitalization of $46.82 billion, a price-to-earnings ratio of 66.97, a PEG ratio of 4.93 and a beta of 0.87.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. The firm had revenue of $4.14 billion during the quarter. Research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.94 EPS for the current fiscal year.

Analyst Ratings Changes

TEVA has been the topic of several research analyst reports. UBS Group increased their price objective on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a research note on Friday, September 4th. Weiss Ratings cut Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, September 8th. Oppenheimer assumed coverage on Teva Pharmaceutical Industries in a research report on Wednesday. They set an “outperform” rating and a $50.00 price target on the stock. Barclays raised their price target on Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Finally, Wall Street Zen downgraded Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Eleven research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $43.73.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Large investors have recently modified their holdings of the business. Cornerstone Planning Group LLC increased its holdings in Teva Pharmaceutical Industries by 547.1% in the 1st quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock worth $27,000 after buying an additional 755 shares during the period. Allworth Financial LP lifted its stake in Teva Pharmaceutical Industries by 53.8% during the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after acquiring an additional 329 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 51.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after acquiring an additional 345 shares during the last quarter. Western Wealth Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the 1st quarter valued at $43,000. Finally, Sunbelt Securities Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the first quarter worth $45,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Key Headlines Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Oppenheimer initiated coverage of Teva Pharmaceutical Industries with an “outperform” rating and a $50 price target, implying meaningful upside from recent trading levels. The firm cited a multi-year product launch cycle and Teva’s transition toward innovative biopharmaceuticals as potential growth drivers. Oppenheimer Teva coverage
• Positive Sentiment: Recent Phase 3 data for once-monthly olanzapine candidate TEV-749, along with additional data for UZEDY, supports investor interest in Teva’s long-acting injectable schizophrenia franchise. The program could create a future growth opportunity if regulatory approval is secured. Teva pipeline update
• Neutral Sentiment: Teva released a Q3 2026 aide-memoire containing previously disclosed information and scheduled its third-quarter earnings release for November 3, 2026, followed by a management conference call. The event gives investors a near-term catalyst, but no new financial guidance was provided. Teva Q3 2026 earnings announcement
• Neutral Sentiment: Short interest surged to approximately 31.5 million shares as of September 15, equal to about 2.7% of shares outstanding and 27.3 days of average trading volume. The positioning signals bearish bets, but could also amplify gains if short sellers cover.
• Negative Sentiment: Director Roberto Mignone sold 367,600 shares for approximately $14.36 million. Separately, Brian Savage sold 7,342 shares, while Teva insiders have recorded 17 sales and no purchases over the past six months. The pattern may weigh on investor confidence after the stock’s strong advance. Teva insider share sale

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. The company develops, manufactures and markets generic medicines, innovative specialty medicines, biosimilars, over-the-counter products and active pharmaceutical ingredients. Its portfolio serves a broad range of therapeutic areas, including central nervous system disorders, respiratory conditions, migraine, oncology and movement disorders.

Teva’s specialty medicines include treatments for conditions such as multiple sclerosis, migraine and tardive dyskinesia, while its generic medicines business supplies products across numerous therapeutic categories and dosage forms.